Abstract
To examine the effect on serum lipase activity and protein concentration of intravenous infusions of glucagon‐like peptide‐1 (GLP‐1) and peptide YY (PYY 3‐36) and of an ad libitum meal in healthy overweight men. Twenty‐five healthy, male subjects participated in this randomized, double‐blinded, placebo‐controlled 4‐arm crossover study (Body Mass Index (BMI): 29 ± 3 kg/m2, age: 33 ± 9 years). On separate days, the subjects received a 150‐min intravenous infusion of either (1) 0.8 pmol/kg/min PYY 3‐36, (2) 1.0 pmol/kg/min GLP‐1, (3) 1 + 2, or (4) placebo. Samples were collected throughout the infusion and after intake of an ad libitum meal for measurement of serum lipase. Serum lipase levels measured by enzyme‐linked immunosorbent assay (ELISA) following mono‐infusions of GLP‐1 and PYY 3‐36 were comparable to serum lipase levels following placebo (P = 0.054 and P = 0.873, respectively). Following the co‐infusion of GLP‐1 and PYY 3‐36, serum lipase levels measured by ELISA decreased over time compared to placebo (P = 0.012). However, the between‐group difference was not consistent when each time point was analyzed separately. On the placebo day, serum lipase levels measured by ELISA after an ad libitum meal rose slightly compared to the preprandial values (P = 0.003). There was strong correlation between serum lipase levels measured by ELISA and LIPC Lipase colorimetric assay (COBAS) (0.94 < r; <0.0001). Infusions of GLP‐1 and PYY 3‐36, separately or in combination, did not increase serum lipase. However, a small increase in serum lipase may occur in response to a meal.
Highlights
Changes in the secretion of the gastro-intestinal hormones, glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), are believed to play an important role for weight loss after Roux-en-Y gastric bypass (RYGB) (le Roux et al 2007; Jacobsen et al 2012)
In a model summarizing the trend for all preprandial time points (30–120 min) and taking baseline differences into account, serum lipase levels following mono-infusions of GLP-1 and PYY3-36 were comparable to serum lipase levels following placebo (P = 0.054 and P = 0.87, respectively) (Figs. 2 and 3)
GLP-1 and PYY3-36, serum lipase levels measured by enzyme-linked immunosorbent assay (ELISA) decreased over time compared to placebo (P = 0.012) (Figs. 2 and 3)
Summary
Changes in the secretion of the gastro-intestinal hormones, glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), are believed to play an important role for weight loss after Roux-en-Y gastric bypass (RYGB) (le Roux et al 2007; Jacobsen et al 2012). Agonists of the GLP-1 receptor (GLP-1R), including exenatide (Byettaâ) and liraglutide (Victozaâ) have been approved for the treatment of T2D and these drugs effectively reduce blood glucose, body weight, and systolic blood pressure. The mechanism by which GLP-1R agonists reduce blood glucose involves potentiation of a 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
